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Abstract
Background: An early prediction of poor outcomes is essential in the management of patients after a
liver resection. The aim of this study was to evaluate the role of selected biochemical parameters on
post-operative day 1 (POD 1) in the prediction of morbidity and mortality after a liver resection for
colorectal metastases.
Method: This retrospective study was based on 236 major liver resections for colorectal metastases
performed between 2006 and 2011. Results of biochemical tests of blood samples obtained on POD 1
were assessed as predictors of primary outcome measures (hepatic and overall morbidity, 90-day
mortality) using multiple regression and receiver-operating characteristics (ROC).
Results: Hepatic morbidity, overall morbidity and 90-day mortality rates were 18.6%, 28.0% and 4.7%,
respectively. On the basis of multiple regression analysis and comparisons of the prediction models,
serum bilirubin was selected for the prediction of hepatic (>2.05 mg/dl, sensitivity 69.2%, specificity
71.2%) and overall (>2.05 mg/dl, sensitivity 61.1% and specificity 71.2%) morbidity, and aspartate
aminotransferase (AST) was selected for the prediction of 90-day mortality (>798 U/l, sensitivity 62.5%
and specificity 90.4%).
Discussion: Biochemical analyses of blood on POD1 enables stratification of patients into low- and
high-risk groups for negative outcomes, with serum bilirubin associated with overall and hepatic
morbidity and AST associated with mortality.
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Introduction
A liver resection is the only potentially radical treatment modality
in patients with metastases from colorectal cancer. Initially, it was
offered only to selected patients according to the number and
distribution of lesions.1 However, the criteria for choosing resec-
tion have significantly evolved in recent years, and currently, the
possibility of oncologically radical removal of all lesions with
special consideration of the future hepatic remnant volume deter-
mines a patient’s eligibility for resective surgery.2 This aggressive
approach in the treatment of patients with metastatic colorectal
cancer is supported by recently reported 5-year overall and
recurrence-free survival rates of 45.2%–58% and 15%–26.2%,
respectively, similar to or higher than the rates in the period of
stricter qualification.3–5
The previously reported post-operative mortality and morbid-
ity rates associated with a liver resection vary widely from 0% to
8.2% and 14.4% to 47.0%, respectively.6–11 Pre- and operative
factors leading to an increased risk of death in the immediate
post-operative period have been extensively investigated and
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include the presence of selected comorbid conditions or a high
Charlson comorbidity index, patient’s age, pre-existing liver dys-
function, operative blood transfusions and extent of liver resec-
tion, among others.7,8,12,13 Given the relatively stable mortality rates
and a tendency towards increasing morbidity rates,3 early predic-
tion and the management of post-operative complications is
crucial for the improvement of short-term outcomes. Considering
pre-operative factors, significant predictors of morbidity include
the American Society of Anesthesiologists score, increased body
mass index, smoking and selected biochemical parameters, among
others.7,11,14 Although pre-operative risk stratification based on
these factors is useful in the evaluation of a patient’s eligibility for
a liver resection, the prediction of morbidity and mortality based
on post-operative factors is potentially more accurate, as such
factors reflect the combined influence of pre-operative status and
intra-operative course. Therefore, several post-operative risk
scores were established previously. These include definitions
of post-hepatectomy liver failure: peak post-operative serum
bilirubin >7 mg/dl;15 the ‘50-50 criteria’ (serum bilirubin concen-
tration >50 mmol/l and prothrombin time <50%);16 and a score
recently proposed by the International Study Group of Liver
Surgery [ISGLS criteria, increased serum bilirubin concentration
and INR (international normalized ratio)].17 Notably, both the
‘50-50 criteria’ and ISGLS definitions are based on evaluation of
serum biochemical tests performed no earlier than post-operative
day (POD) 5.
There are few up-to-date studies concerning normal fluctua-
tions of biochemical blood parameters after a liver resection.
According to Reissfelder et al., serum bilirubin, the (INR), and
activity of aspartate (AST) and alanine (ALT) aminotransferase
usually return to normal values during the first 5 to 7 post-
operative days after an immediate post-operative increase.18
However, significant differences regarding some of these factors,
particularly serum bilirubin, may be observed as early as POD 1
between patients with and without post-operative complications.
The aim of this study was to evaluate the prognostic significance
of the serum bilirubin concentration, INR, AST and ALT on POD
1 for mortality and morbidity after a liver resection, with a special
focus on the occurrence of hepatic complications.
Methods
This retrospective cohort study was based on data from 236
patients after a major liver resection for colorectal metastases per-
formed between January 2006 andMarch 2011 in the Department
of General, Transplant and Liver Surgery, Medical University of
Warsaw (Poland). Major resections were defined as removal
of three or more segments according to Couinaud’s divisions.
Patients undergoing a liver resection combined with radiofre-
quency or crioablation (n = 10) procedures were excluded. The
exact details of the pre-operative assessment and operative tech-
nique were previously reported.19 Briefly, all patients underwent
ultrasonography, computed tomography and/or magnetic reso-
nance imaging for evaluation of liver pathology and volume of the
remnant liver post-hepatectomy. The minimum volume of the
remnant liver in patients considered eligible for a liver resection
was approximately 30%, depending on the results of pre-operative
biochemical tests and quality of liver parenchyma assessed intra-
operatively. The Pringle manoeuvre was used selectively when
faced with increased bleeding. The serum bilirubin concentration,
INR and activity of AST and ALT were evaluated routinely on
POD 1 (12–18 h post-operatively), and again in most patients, on
PODs 2–3. At later post-operative times, these biochemical tests
were performed at various time intervals, depending on the
post-operative course.
Both in-hospital and 90-day mortality rates were calculated,
with the second being one of the primary outcome measures.
Others included occurrence of overall and hepatic complications,
a group comprising post-operative liver failure, delayed recovery
of liver function, biliary leak and subphrenic abscess. Patients with
post-operative liver failure were defined as those with peak serum
bilirubin levels exceeding 7 mg/dl, while delayed recovery of liver
function was defined by occurrence of any of the clinical signs of
liver insufficiency with a peak serum bilirubin level below 7 mg/dl.
Associations between serum bilirubin concentration, INR, and
activity of AST and ALT on POD 1 with overall and hepatic
morbidity, as well as with 90-day mortality, were evaluated in
univariate and multiple analyses. Moreover, univariate analyses
were performed using logistic regression with splines functions
for quantitative variables. Multiple logistic regression analysis
[Logistic Procedure of the SAS System (SAS Institute, Cary, NC,
USA)] and generalized additive models (gam function of S-Plus)
were used to assess independent biochemical predictors of overall/
hepatic complications and death within the 90-day post-operative
period. Receiver operating characteristics (ROC) curves were used
to indicate approximate cut-off values for independent predictors.
Sensitivity and specificity rates, as well as positive (PPV) and
negative (NPV) predictive values, were estimated. Hazard ratios
(HRs) and areas under the curves (AUCs) are presented with 95%
confidence intervals. The Mann–Whitney U-test was used for
AUC comparisons. SAS System v. 9.3 and S-Plus v. 6.1 were
applied for computing statistical analyses. The level of statistical
significance was set at 0.05.
Results
Baseline characteristics of the study cohort are shown in Table 1.
The overall morbidity rate was 28.0% (66 of 236), including the
18.6% (44 of 236) rate of patients developing hepatic complica-
tions. More specifically, postoperative liver failure occurred in 8
(3.4%) patients, delayed recovery of liver function in 26 (11.0%)
patients, biliary leak in 12 (5.1%) patients, and subphrenic abscess
in 2 (0.8%) patients. In-hospital and 90-day mortality rates were
2.1% (5 of 236) and 4.7% (11 of 236), respectively. The exact
causes of death were only known for patients who died during
post-operative hospitalization and included the following: post-
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operative liver failure in two patients and sepsis and peri-operative
bleeding in one patient each. The fifth patient died during implan-
tation of a Y-graft due to peripheral emboli.
Univariate and multiple analyses of the associations between
biochemical parameters on POD 1 and the 3 main outcomemeas-
ures are presented in Table 2. According to the spline functions
derived from generalized additive models, all of the observed asso-
ciations were of a linear nature (all P for non-linear associations >
0.05; Fig. 1).
Regarding hepatic morbidity, areas under the ROC curves were
0.780 [95% confidence interval (CI), 0.698–0.862] for the predic-
tive model based on both serum bilirubin concentration and INR,
0.737 (95% CI, 0.645–0.828) for the model based only on serum
bilirubin concentration, and 0.714 (95% CI, 0.624–0.804) for the
model based only on INR. Area under the ROC curve for the
model predicting hepatic complications based solely on serum
bilirubin concentration was statistically non-inferior to those
based both on serum bilirubin concentration and INR (P <
0.162). Therefore, this model was chosen for the prediction of
hepatic complications, with an approximate cut-off value of
2.05 mg/dl of serum bilirubin, providing a sensitivity of 69.2%,
specificity of 71.2%, PPV of 39.1% and NPV of 89.7% (Fig. 2).
Similarly, there were no significant differences between the pre-
diction model based on both serum bilirubin concentration and
INR (AUC, 0.749; 95% CI, 0.672–0.827) and the model limited to
only serum bilirubin (AUC, 0.690; 95% CI, 0.604–0.776) with
respect to overall morbidity (P < 0.099). The prediction of overall
morbidity based on serum bilirubin concentration exhibited a
sensitivity of 61.1%, specificity of 71.2%, PPV of 44.0% and NPV
of 83.2% for values equal or over 2.05 mg/dl (Fig. 3). Finally,
regarding the prediction of 90-day mortality, the area under the
ROC curve for the model based on AST activity was 0.644 (95%
CI, 0.353–0.936) with a sensitivity of 62.5%, specificity of 90.4%,
PPV of 20.8% and NPV of 98.3% for values equal or over 798 U/l
(Fig. 4). Notably, the prediction model for 90 day-mortality based
on both AST and ALT was not associated with any significant
benefits compared with the model based only on AST (P < 0.141).
Eight patients fulfilled the criteria of post-operative liver failure
according to the definition based on peak serum bilirubin con-
centration over 7 mg/dl, and two patients fulfilled the ‘50-50 cri-
teria’ on POD 5. The sensitivity for the prediction of hepatic
morbidity, overall morbidity and 90-day mortality was approxi-
mately three-fold higher for the criteria based on peak serum
bilirubin concentration compared with the ‘50-50 criteria,’ with
similar specificity. Details concerning comparison of these two
different criteria are presented in Table 3.
Discussion
The results of this study highlight the previously underestimated
role of biochemical parameters on POD 1 in the early prediction
of poor outcomes after major resections for colorectal liver
metastases. Notably, effective biochemical predictors were differ-
ent for morbidity and mortality. While serum bilirubin and INR
were associated with the occurrence of hepatic and overall com-
plications, post-operative mortality was best predicted by AST
activity, with the serum bilirubin concentration not reaching sig-
nificance. This finding was rather unexpected, given that the
activity of transaminases was not considered in post-operative
mortality risk scores, such as those proposed by Mullen et al. on
the basis of peak serum bilirubin levels,15 the ‘50-50 criteria’ by
Balzan et al. 16 and in a definition of post-operative liver insuf-
ficiency published by the International Study Group for Liver
Surgery.17
Table 1 Baseline characteristics of the study cohort
Factors All patients
(n = 236)
Patient factors
Gender
Male 126 (53.4)
Female 110 (46.6)
Age 60 (54–67)
Pre-operative biochemical parameters
Serum bilirubin (mg/dl) 0.6 (0.4–0.8)
INR 1.01 (0.98–1.06)
AST (U/l) 31 (24–39)
ALT (U/l) 27 (20–39)
Comorbidity
Diabetes mellitus 29 (12.3)
Hypertension 60 (25.4)
Cardiovascular disease 16 (6.8)
COPD 6 (2.5)
Hepatic steatosis
Absent 127 (53.8)
30% or less 90 (38.1)
31–50% 5 (2.1)
> 50% 4 (1.7)
Missing 10 (4.2)
Recurrence of liver metastases 29 (12.3)
Operative factors
Extent of resection
Three segments 16 (6.8)
Four segments 139 (58.9)
Five segments 77 (32.6)
Six segments 4 (1.7)
Pringle manoeuvre 74 (31.4)
Blood transfusions, yes 50 (22.9)a
Plasma transfusions, yes 43 (19.7)a
Total operative time (hours) 4.3 (3.5–5.0)
aData available for 218 patients.
Data are presented as n (%) or median (interquartile range); INR, inter-
national normalized ratio; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; COPD, chronic obstructive pulmonary disease.
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Considering the prediction of hepatic and overall complica-
tions, both the serum bilirubin concentration and INR on POD 1
retained significance in a multiple regression model. Given that
INR values are potentially influenced by peri-operative plasma
transfusions, prediction models based solely on serum bilirubin
concentration were compared with models including both of
these parameters. The results of this comparison indicated non-
inferiority, and thus, the bilirubin-only prediction was considered
in further analyses for both outcome measures.
Notably, the empirically established predictive cut-off value for
serum bilirubin concentration on POD 1 >2.05 mg/dl regarding
both hepatic and overall morbidity, and for serum AST activity
>798 U/l regarding 90-day mortality did not allow precise
discrimination between patients with poor and uneventful
post-operative course. Nevertheless, these cut-off points exhibit
moderate sensitivity and specificity and might be useful in strati-
fying patients into low- and high-risk groups as early as POD 1 for
particular outcomemeasures. Because these results originate from
a series of patients treated in a single centre and the number of
end-points was limited, external validation is obviously essential
to adequately assess their clinical significance in terms of preven-
tion, early diagnosis and the management of particular events.
Short-term outcomes of patients in this series are similar to
those reported by other authors.7–9,11–16,20 In one of the previous
studies based on an unselected series of 1005 liver resections per-
formed in the Department of General, Transplant and Liver
Surgery at the Medical University of Warsaw, overall morbidity
and mortality rates were 22.1% and 1.4%, respectively.19 Although
several studies have reported zero or near-zero mortality after a
liver resection, most of these report only in-hospital or 30-day
rates.6,21–23 Of note, in-hospital mortality was more than two-fold
lower compared with the 90-day rate in the present series. There-
fore, all deaths occurring during the 90-day post-operative period
should be considered in the evaluation of mortality rates, as this
allows a more precise comparison between different studies and
avoids underestimation of rates.Of note, this observation is in line
with those of other reports focused on short-term outcomes after
a liver resection.9,14,15,24
There are two main methodological advantages of the present
study. First, it was performed on a rather homogenous group of
non-cirrhotic patients only after major liver resections for color-
ectal metastases. Second, although the design was retrospective,
biochemical parameters included in the analyses were performed
routinely on POD 1 in all patients. This minimizes potential selec-
tion bias that could affect analyses of these parameters on later
post-operative days.
Out of three main definitions for post-hepatectomy liver
failure, criteria based on peak bilirubin >7 mg/dl were applied.
These were proposed by Mullen et al. based on a large series of
non-cirrhotic patients after a major hepatectomy, a cohort similar
to those included in the present study.15 Conversely, the ‘50-50
criteria’ were initially created in a slightly more heterogeneous
group of patients.16 Although both were highly specific, the rate of
sensitivity for predicting 90-day mortality was rather low. Never-
theless, comparison of these two criteria revealed that the defini-
tion used in this study was approximately three times more
sensitive regarding mortality rate than the ‘50-50 criteria’ on POD
5. This may be partly related to the previously mentioned similar-
ity between the cohorts of patients included in this study and
those studied by Mullen et al.15 However, our results obviously do
not rule out the potential superiority of the ‘50-50 criteria’ inmore
heterogeneous groups.
The limitations of this study are mainly related to its retro-
spective approach. Accordingly, to avoid both under- and
Table 2 Associations between selected serum biochemical parameters on post-operative day 1 and hepatic morbidity, overall morbidity, and
90-day mortality in univariate and multiple analyses
Outcome measure Biochemical parameter ORs calculated per: Univariate Multiple
OR 95% CI P OR 95% CI P
Hepatic morbidity Bilirubin 1.0 mg/dl 1.75 1.31–2.34 <0.001 1.57 1.14–2.17 0.006
INR 0.1 1.37 1.16–1.62 <0.001 1.25 1.03–1.51 0.024
AST 100 U/l 1.09 1.01–1.19 0.039 – – –
ALT 100 U/l 1.10 1.01–1.21 0.034 – – –
Overall morbidity Bilirubin 1.0 mg/dl 1.61 1.24–2.09 <0.001 1.43 1.07–1.91 0.015
INR 0.1 1.40 1.21–1.63 <0.001 1.31 1.11–1.54 0.001
AST 100 U/l 1.06 0.98–1.15 0.128 – – –
ALT 100 U/l 1.08 0.99–1.18 0.069 – – –
90-day mortality Bilirubin 1.0 mg/dl 1.33 0.83–2.12 0.242 – – –
INR 0.1 1.29 0.99–1.67 0.062 – – –
AST 100 U/l 1.16 1.05–1.29 0.005 1.16 1.05–1.29 0.005
ALT 100 U/l 1.17 1.04–1.32 0.011 – – –
OR, odds ratio; 95% CI, 95% confidence intervals; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
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overestimation, complications were not stratified according to
Clavien–Dindo classification.25 Second, although the study cohort
was relatively homogenous with respect to the extent of resection
and histopathology of the non-tumoral liver, the small number of
specific events precluded more complex prediction regarding
these two important factors. Moreover, multiple logistic regres-
sion analyses used to evaluate independent predictors of 90-day
mortality might have been biased by the low number of events. As
Table 3 Comparison of the criteria for post-operative liver failure based on peak post-operative serum bilirubin > 7 mg/dl and ‘50-50 criteria’
on post-operative day 5 in the prediction of hepatic morbidity, overall morbidity and 90-day mortality
Outcome measure ‘50-50 criteria’ on post-operative day 5 Peak serum bilirubin concentration > 7 mg/dl
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
Hepatic morbidity 4.6% 100% 100% 82.1% 18.2% 100% 100% 84.2%
Overall morbidity 3.0% 100% 100% 72.7% 12.1% 100% 100% 74.6%
90-day mortality 9.1% 99.6% 50.0% 95.7% 27.3% 97.8% 37.5% 96.5%
PPV, positive predictive value; NPV, negative predictive value.
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Figure 1 Associations between serum bilirubin concentration, international normalized ratio (INR), and activity of aspartate (AST) and alanine
aminotransferases (ALT) on post-operative day 1 with hepatic morbidity (a), overall mortality (b) and 90-day mortality (c). Hazard curves (solid
lines) are presented with 95% confidence intervals (dotted lines)
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this particular selection process was based only upon bivariate
analyses, the absolute number of events per variable was 5.5 (11
deaths observed during the 90-day period). Considering the
minimum of five events per variable reported in epidemiological
studies,26 multiple logistic regression was in this case slightly above
the verge of applicability. Therefore, models based on both AST
and ALT (the second significant factor in univariate analyses)
activity and solely on AST activity were compared. The lack of
significant differences additionally supported the choice of AST as
a predictor of 90-day mortality.
In summary, the serum bilirubin concentration and activity of
AST on post-operative day 1 allow stratification of patients into
low- and high-risk groups of morbidity and mortality after a liver
resection, respectively. These results provide additional tools for
early prediction and management of poor outcomes after a hepa-
tectomy for colorectal metastases.
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